RELATING TO OPIOID USE DISORDER TREATMENT.
SB2505 establishes a two-year pilot program to allow certain licensed paramedics in Hawaii to administer buprenorphine after giving naloxone to a patient experiencing a suspected opioid overdose. The bill is aimed at improving immediate post-overdose care by reducing withdrawal symptoms and increasing the likelihood that patients engage in opioid use disorder treatment soon after the emergency encounter.
The program is limited at first to one county with a population of 100,000 or less, and it can expand statewide if treatment resources become available. To participate, paramedics must complete department-approved training, follow department of health protocols, and refer patients to a designated treatment provider within the same day or next day. The Department of Health must also identify treatment centers that can accept patients within 24 to 48 hours and coordinate among EMS, emergency departments, and substance use disorder treatment programs.
The bill also requires the Department of Health to evaluate the pilot and report to the legislature within 20 months on patient numbers, withdrawal outcomes, follow-up treatment engagement, operational challenges, and recommendations for expansion or further legislation. The measure includes an appropriation from general revenues for fiscal year 2026-2027 and sunsets on June 30, 2028, at which point the amended statute would revert to its prior form unless further legislation is enacted.
The bill’s impact on state law is to temporarily amend Hawaii Revised Statutes section 329E-3 to expand the authority of emergency responders, specifically paramedics in a small county, from administering opioid antagonists to also administering buprenorphine under defined conditions. It creates new duties for the Department of Health to adopt rules, certify treatment access, train paramedics, and oversee data collection and reporting, while leaving the broader statewide framework unchanged unless the pilot is later expanded.
The general sentiment around the bill appears supportive and pragmatic, with the Senate Health and Human Services Committee advancing it unanimously, 5-0, with amendments. The bill’s framing emphasizes evidence-based treatment and a targeted response to the opioid crisis, suggesting broad agreement on the need for better post-overdose intervention.
The main point of contention is not whether to address opioid overdoses, but how to do so safely and effectively. The bill reflects concern about ensuring rapid follow-up treatment after field administration of buprenorphine, which is why it limits the pilot geographically, requires training and protocols, and conditions implementation on available treatment capacity. Those safeguards suggest that access to downstream care and operational readiness are the key issues driving the bill’s narrow, phased approach.
SB2505 would temporarily amend section 329E-3, Hawaii Revised Statutes, to authorize trained paramedics in a county with a population of 100,000 or less to administer buprenorphine after naloxone in suspected opioid overdose cases, subject to Department of Health protocols and referral requirements. It also imposes new Department of Health duties to adopt rules, designate treatment providers, train paramedics, coordinate care, and report on program outcomes. The measure creates a limited pilot program with a sunset date, so the statutory change is temporary unless later extended or made permanent.
The available voting history indicates strong support, with the Senate Health and Human Services Committee passing the bill 5-0 with amendments. The bill’s purpose is framed as a public health response to the opioid crisis, and the discussion reflected in the text emphasizes evidence-based treatment, improved linkage to care, and a cautious pilot structure. Overall, the sentiment appears favorable and policy-driven rather than partisan or highly divided.
The principal concern reflected in the bill is implementation rather than opposition to the underlying concept. The Department of Health’s stated concern about ensuring follow-up treatment within 24 to 48 hours is addressed by limiting the pilot to a small county, requiring same-day or next-day referrals, and conditioning expansion on available treatment resources. Any contention is therefore centered on patient safety, treatment access, training, and operational capacity for EMS and treatment providers, rather than on whether buprenorphine should be used at all.